A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

About this Study

The objective of Study M14-675 (Phase 3 induction) is to evaluate the efficacy and safety of upadacitinib 45 mg once daily (QD) compared to placebo in inducing clinical remission (per Adapted Mayo score) in subjects with moderately to severely active ulcerative colitis (UC).

Sponsor Protocol ID:M14-675
IRB Number:2020-0032
Actively Enrolling
Interventional
Phase 3
February 21, 2020
Eligibility Criteria
18 years old
75 years old
Both Male and Female
No
No
No

Inclusion CriteriaMale or female between 18 and 75 years of age at Baseline.

 Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit. 

If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol: Contraception Recommendations.

Exclusion CriteriaSubject with current diagnosis of Crohn's disease 

Categories Click category to view its trials.
Digestive Conditions
Participating Locations
Belhaven Building - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Yilianys Pride
Phone Number: 601-496-2009
Email: ypride@umc.edu
Principal Investigator:Glover, Sarah C, D.O.
How to participate in our Clinical Trials